Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First in human clinical trial assessing iTOL 102

Next Previous
Search
Trial Profile

First in human clinical trial assessing iTOL 102

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 10 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ITOL 102 (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions; First in man

Most Recent Events

  • 18 Mar 2025 According to an iTolerance, Inc media release, company received US $1.0 million grant from BIRD foundation, the funding will be used to support clinical application of iTOL-102.
  • 10 Mar 2025 New trial record
  • 25 Feb 2025 According to NLS Pharmaceutics media release, the company announced that Kadimastem and iTolerance successfully completes a pre-IND meeting with the US FDA for iTOL 102 for the treatment of type 1 diabetes mellitus and in preparation of this first in human trial

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top